title: [Total body irradiation, vincristine in continuous infusion and high-dose melphalan with transplant of autologous bone marrow in the treatment of neuroblastoma].
abstract: High dose chemo-radiotherapy followed by autologous bone marrow transplantation (ABMT) is known to be an effective treatment in stage IV neuroblastoma (NB). Since October '84, 19 children with NB (12 relapsed or resistant: Group A; 7 in first CR: Group B) received ablative therapy (AT) consisting of VCR (4 mg/mg), L-PAM (140 mg/mg) and fractionated TBI (1000 Rads). Induction strategy at diagnosis or at relapse included high dose Peptichemio, 2-3 cycles of Vincristine-Cyclophosphamide--high dose Platinum and surgery. Bone marrow was harvested after 2 evaluation proved negative by cytomorphology, histology and immunofluorescence. Mononuclear cells (median 6.7 x 10(7)/kg) were cryopreserved and reinfused without purging. At the time of AT in Group A8 children were in CR, 4 had minimal diseases; in Group B 6 were in CR and one in PR. One toxicity-related death occurred on day 7 in a child in first CR; median duration of granulocytopenia 0.5 x 10(9)/l and thrombocytopenia less than 50 x 10(9)/l were 20 days (R: 9-40) and 27 days (R: 11-51) respectively. Persistent immune thrombocytopenia occurred in 4 children. Fever higher tha 38 degrees C developed in all patients: sepsis was documented in 6 patients. Extramedullary toxicity was moderate: GI tract was the most affected. Two out of 5 children who received AT having residual disease achieved CR; relapse or progression of disease occurred in all these patients. Four out of 8 children in second or subsequent CR and 4 out of 5 in first CR are alive and well at 3-12 months (median 7).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.forename: G
authors.initials: G
authors.lastname: Dini
authors.forename: A
authors.initials: A
authors.lastname: Garaventa
authors.forename: E
authors.initials: E
authors.lastname: Lanino
authors.forename: G P
authors.initials: GP
authors.lastname: Perin
authors.forename: D
authors.initials: D
authors.lastname: Scarpati
authors.forename: C
authors.initials: C
authors.lastname: Viscoli
authors.forename: E
authors.initials: E
authors.lastname: Franchini
authors.forename: R
authors.initials: R
authors.lastname: Corvò
authors.forename: S
authors.initials: S
authors.lastname: Dallorso
authors.forename: G
authors.initials: G
authors.lastname: Cinollo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007223:Infant; D007239:Infections / Q000209:etiology; D007262:Infusions, Intravenous; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009503:Neutropenia / Q000150:complications; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*; D014916:Whole-Body Irradiation
chemical_list: D014750:Vincristine; D008558:Melphalan
vernacular_title: Irradiazione corporea totale, vincristina in infusione continua e melfalan ad alte dosi con trapianto di midollo autologo nel trattamento del neuroblastoma.